Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness
dc.contributor.author | Harrington, K. | |
dc.contributor.author | Lim, Y. | |
dc.contributor.author | Ames, D. | |
dc.contributor.author | Hassenstab, J. | |
dc.contributor.author | Laws, Simon | |
dc.contributor.author | Martins, R. | |
dc.contributor.author | Rainey-Smith, S. | |
dc.contributor.author | Robertson, J. | |
dc.contributor.author | Rowe, C. | |
dc.contributor.author | Salvado, O. | |
dc.contributor.author | Doré, V. | |
dc.contributor.author | Villemagne, V. | |
dc.contributor.author | Snyder, P. | |
dc.contributor.author | Masters, C. | |
dc.contributor.author | Maruff, P. | |
dc.date.accessioned | 2018-12-13T09:15:22Z | |
dc.date.available | 2018-12-13T09:15:22Z | |
dc.date.created | 2018-12-12T02:46:58Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Harrington, K. and Lim, Y. and Ames, D. and Hassenstab, J. and Laws, S. and Martins, R. and Rainey-Smith, S. et al. 2017. Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 8: pp. 156-164. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/73085 | |
dc.identifier.doi | 10.1016/j.dadm.2017.05.006 | |
dc.description.abstract |
© 2017 The Authors Introduction High levels of amyloid ß (Aß) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aß-) and high (Aß+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aß- group, the Aß+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aß+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness. | |
dc.title | Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness | |
dc.type | Journal Article | |
dcterms.source.volume | 8 | |
dcterms.source.startPage | 156 | |
dcterms.source.endPage | 164 | |
dcterms.source.issn | 2352-8729 | |
dcterms.source.title | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring | |
curtin.department | School of Pharmacy and Biomedical Sciences | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |